New gene therapy for rare inherited disorder causing vision loss recommended for approval
Luxturna is the first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna (voretigene neparvovec), for the treatment of adults and children suffering from inherited retinal dystrophy caused by RPE65 gene mutations, a rare genetic disorder which causes vision loss and usually leads to blindness.
The mutations of the RPE65 gene, which encodes one of the enzymes involved in the biochemistry of light capture by the cells of the retina, hinder the patient’s ability to detect light. It is a severely debilitating disease, characterised by a progressive loss of vision. Most patients will be blind by the time they are young adults. There is currently no treatment for this disease; support to patients is limited to measures allowing the management of the disease such as aids for low vision.
Luxturna is meant for patients with confirmed biallelic mutations of the RPE65 gene (i.e. patients who have inherited the mutation from both parents) and who have sufficient viable retinal cells. It is the first gene therapy to be recommended for approval for a retinal disease. Luxturna works by delivering a functional RPE65 gene into the cells of the retina through a single retinal injection, which restores the production pathway for the required enzyme thereby improving the patient’s ability to detect light.
Luxturna was studied in 41 patients. In the main clinical trial supporting the approval of Luxturna, patients treated with the medicine showed a significant improvement of night vision, one of the typical symptoms of the disease, after one year, while no improvement was seen in the control group. The most common side effects were conjunctival hyperaemia (eye redness), cataracts and increased intraocular pressure.
Given the novelty of the treatment and the limited number of treated patients, the CHMP requires the company to ensure the long-term follow-up of patients to confirm Luxturna’s continuing efficacy and safety. Follow-up studies were agreed, including a post-authorisation safety study (PASS) based on a disease registry in patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations, as well as a 15-year follow-up programme of efficacy and safety outcomes for all patients treated in the clinical programme.
The CHMP’s opinion is based on the assessment by EMA’s expert committee on Advanced Therapy Medicinal Products (ATMPs), the Committee for Advanced Therapies(CAT). Luxturna was designated as an orphan medicine and an ATMP and EMA provided protocol assistance to the applicant during the development of the medicine.
The opinion adopted by the CHMP is an intermediary step on Luxturna’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once the marketing authorisation has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for Luxturna is Spark Therapeutics Ireland Ltd.
- As always at time of approval, EMA’s Committee for Orphan Medicinal Products (COMP) will review the orphan designation to determine whether the information available to date allows maintaining Luxturna’s orphan status and granting this medicine ten years of market exclusivity.
|New gene therapy for rare inherited disorder causing vision loss recommended for approval||(English only)||21/09/2018|
Latest News from
Trendspotter manual: a handbook for the rapid assessment of emerging drug-related trends14/12/2018 13:20:00
This publication is a user-friendly guide, taking the reader, step by step, through the trendspotter methodology developed by the EMCDDA to explore emerging drug trends, new patterns of use, developing drug markets and technologies.
EU negotiators agree to facilitate access to online TV and radio content across borders14/12/2018 11:37:00
The negotiators of the EC, the European Parliament and the Council, have reached a political agreement on the proposed copyright legislation on TV and radio programmes.
Agreement on EC proposal to boost the use of organic and waste-based fertilisers13/12/2018 16:25:00
The EU institutions have found an agreement on new EU rules on fertilisers proposed by the EC in 2016 as a key deliverable of the Circular Economy Package.
European Citizens' Initiative: Political agreement reached on the EC’s proposal13/12/2018 14:37:00
The European Parliament and the Council reached a political agreement on the EC’s proposal to revise the European Citizens' Initiative, an instrument which allows 1m European citizens to ask the Commission to submit a legislative proposal.
EU-Japan trade agreement on track to enter into force in February 201913/12/2018 13:10:00
The trade agreement negotiated by the EC is the first ever to include an explicit reference to the Paris climate agreement. It will create an open trading zone covering 635m people and almost one third of the world's total GDP.
Multiannual management plan for Western Waters: provisional agreement confirmed by the Council13/12/2018 12:25:00
The management of fisheries in Western waters will soon benefit from a longer term and more consistent set of rules established jointly by all EU institutions.
Import of fishery products: Council agrees on autonomous EU tariff quotas for the period 2019-202013/12/2018 11:10:00
In 2019 and 2020 the EU fish processing industry will continue to import raw material for further processing from non-EU countries at reduced rates or duty free.
Extended internal market and EU relations with non-EU Western European countries13/12/2018 09:25:00
Council conclusions on a homogeneous extended internal market and EU relations with non-EU Western European countries